相关实验视频

Updated: Jun 8, 2025

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Published on: January 25, 2015

在患有晚期黑色素瘤的患者中,使用尼沃卢马布加上伊皮利穆马布或尼沃卢马布单独结合的长期结局

Georgina V Long¹, James Larkin², Dirk Schadendorf³

¹Melanoma Institute Australia and Royal North Shore and Mater Hospitals, The University of Sydney, Sydney, NSW, Australia.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

|November 6, 2024

概括

与尼沃卢马布单独治疗相比,尼沃卢马布加伊皮利穆马布联合治疗在患有晚期黑色素瘤的患者中显示了较长的整体存活期. 这项分析确定了影响两种免疫检查点抑制剂治疗的生存结果的临床因素.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
黑色素瘤研究黑色素瘤研究

背景情况:

尼沃卢马布 (NIVO) 和伊皮利穆马布 (IPI) 是免疫检查点抑制剂 (ICI),用于治疗不可切除/转移性黑色素瘤.
无论是NIVO + IPI组合治疗还是NIVO单一治疗,在晚期黑色素瘤患者中都显示出持久的临床益处.
了解长期存活率和预测因素对于优化ICI-naive患者的治疗策略至关重要.

研究的目的:

为了比较ICI治疗先前未经切除/转移性黑色素瘤患者的NIVO+IPI组合和NIVO单疗之间的长期整体存活率 (OS).
在接受NIVO + IPI或NIVO单一治疗的患者中确定与生存结果相关的临床因素.

主要方法:

汇集了来自六个公司赞助的CheckMate研究的数据,这些研究涉及ICI治疗先前的患者.
患者接受了NIVO + IPI (两种不同的剂量方案) 或NIVO单疗法 (3 mg/kg).
总生存率 (OS) 通过使用Cox比例多变量分析 (MVA) 和分类和回归树 (CART) 分析进行了分析.

主要成果:

随访时间中位数为45.0个月 (NIVO + IPI) 和35.8个月 (NIVO),NIVO + IPI显示较长的OS (6年OS率:52%对41%).
在BRAF突变状态和乳酸脱酶 (LDH) 水平上观察到一致的生存益处.
与生存率降低相关的临床因素包括较高的LDH,65岁以上的年龄 (用NIVO + IPI),以及肝转移 (用NIVO单独治疗).

结论:

与尼沃卢马布单独治疗相比,尼沃卢马布加伊皮利穆马布组合疗法在晚期黑色素瘤患者中提供更好的长期整体存活率.
这项回顾性分析确定了关键的临床因素 (LDH,年龄,肝转移),这些因素可能有助于ICI先前患者的治疗决策.
这些发现支持组合免疫疗法的疗效,并强调患者特异性因素在预测存活率方面的重要性.

更多相关视频

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

Minimally Invasive Isolated Limb Perfusion (MI-ILP) for Locally Advanced Melanomas and Sarcomas of the Extremity

Minimally Invasive Isolated Limb Perfusion (MI-ILP) for Locally Advanced Melanomas and Sarcomas of the Extremity

Published on: January 31, 2025

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Skin Cancer

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...